Pacts In Medtech, July/August 2016
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
You may also be interested in...
New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech
Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.
Financing Quarterly Statistics, Q3 2021
For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.
Deals In Depth: September 2021
Three $1bn+ alliances were penned in September. Topping the list was a potential $3.25bn deal between Adaptimmune Therapeutics and Roche's Genentech for the development and commercialization of allogeneic T-cell therapies in multiple oncology indications. Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell-derived allogeneic platform to produce T-cells. Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization. Adaptimmune has the right to opt in to a 50/50 US profit/cost share on off-the-shelf products.